journal article·2026-04Open access

Identification of A p300–SP1–BRD4 Transcriptional Axis as a Key Driver of AR Hyperactivation in Polycystic Ovarian Syndrome

Zhengquan Zhu, Yihan Wang, Haiyun Chen, Xinye Yu, Tingyu Wang, Yajing Weng, Meihong Guo, Ying Huang, Gaojian Tao, Wangsen Cao, Yong Wang, Daojuan Wang

Advanced Science· Volume 13· Issue 23

Abstract

ABSTRACT Persistent androgen receptor (AR) activation is an important contributor to polycystic ovary syndrome (PCOS) and is affected by transcriptional regulation via histone acetylation; however, the underlying mechanisms are partially understood. This study demonstrated that AR activation in ovarian granulosa cells (GCs) of both dehydroepiandrosterone (DHEA) and high‐fat diet‐induced PCOS mouse models correlated with a significant increase in the histone acetyltransferase p300 and histone acetylation. Conversely, GC‐specific p300 knockout or pharmacological inhibition with C646/A‐485 effectively reduced AR activation, histone 3 acetylation (H3K18ac/H3K27ac), and ovarian fibrosis in PCOS mice, highlighting p300 as a critical driver. ATAC‐seq and RNA‐seq identified “open” chromatin regions at the AR promoter in PCOS ovaries, corresponding with increased AR transcription and histone acetylation. p300, along with transcription factor SP1 and the acetyl‐reader BRD4, bound to H3K18ac and H3K27ac of the AR promoter in PCOS‐modeled ovaries and GCs, which was blocked by C646 and the SP1 inhibitor Plicamycin, respectively. Importantly, continuous AR activation by its ligand DHT largely diminished the anti‐fibrotic and ovarian‐protective effects of C646. These findings suggest that p300, SP1, and BRD4, form a critical transcriptional complex driving AR activation and PCOS development, and that targeting the p300/AR axis may present a promising therapeutic approach for treating PCOS.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Ovarian function and disorders · Sexual Differentiation and Disorders · Hormonal and reproductive studies

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Pain Management Nanjing Drum Tower Hospital Affiliated Hospital of Medical School Nanjing University Nanjing China

Department of State Key Laboratory of Analytical Chemistry For Life Science and Jiangsu Key Laboratory of Molecular Medicine Medical School of Nanjing University Nanjing China

Department of Nephrology Yangzhou Precision Research Institute of Kidney Disease Northern Jiangsu People's Hospital Teaching Hospital of Nanjing University Medical School Yangzhou China

Funding

National Natural Science Foundation of China

References (48)

Show source-provided references
1. 10.1038/nrendo.2010.21710.1038/nrendo.2010.217 ↗
2. 10.1016/j.fertnstert.2024.01.01810.1016/j.fertnstert.2024.01.018 ↗
3. 10.1210/er.2015‐101810.1210/er.2015‐1018 ↗
4. 10.1016/j.tem.2014.12.00310.1016/j.tem.2014.12.003 ↗
5. 10.1080/19490976.2022.208596110.1080/19490976.2022.2085961 ↗
6. 10.1093/humupd/dmad00510.1093/humupd/dmad005 ↗
7. 10.1093/humupd/dmw02710.1093/humupd/dmw027 ↗
8. 10.1016/j.ebiom.2020.10305810.1016/j.ebiom.2020.103058 ↗
9. 10.1186/s12967‐020‐02249‐410.1186/s12967‐020‐02249‐4 ↗
10. 10.1016/j.scitotenv.2020.14104910.1016/j.scitotenv.2020.141049 ↗
11. 10.1093/nar/gkac115810.1093/nar/gkac1158 ↗
12. 10.1074/jbc.REV120.01241110.1074/jbc.REV120.012411 ↗
13. 10.1016/j.mce.2017.08.01610.1016/j.mce.2017.08.016 ↗
14. 10.1093/procel/pwad06510.1093/procel/pwad065 ↗
15. 10.1016/j.beem.2015.04.00510.1016/j.beem.2015.04.005 ↗
16. 10.1038/sj.pcan.450093610.1038/sj.pcan.4500936 ↗
17. 10.1016/j.jgr.2021.11.00510.1016/j.jgr.2021.11.005 ↗
18. 10.1002/med.2155810.1002/med.21558 ↗
19. 10.1016/j.mam.2016.10.00110.1016/j.mam.2016.10.001 ↗
20. 10.1186/s13148‐021‐01119‐010.1186/s13148‐021‐01119‐0 ↗
21. 10.1038/s41588‐020‐0681‐710.1038/s41588‐020‐0681‐7 ↗
22. 10.1016/j.celrep.2019.04.10110.1016/j.celrep.2019.04.101 ↗
23. 10.1210/jc.2018‐0005210.1210/jc.2018‐00052 ↗
24. 10.7150/ijbs.8048110.7150/ijbs.80481 ↗
25. 10.1038/onc.2015.29510.1038/onc.2015.295 ↗
26. 10.1016/j.celrep.2023.11309010.1016/j.celrep.2023.113090 ↗
27. 10.1038/nature2402810.1038/nature24028 ↗
28. 10.1038/s41580‐018‐0081‐310.1038/s41580‐018‐0081‐3 ↗
29. 10.1016/j.cbpa.2015.10.03010.1016/j.cbpa.2015.10.030 ↗
30. 10.1080/15548627.2023.220035210.1080/15548627.2023.2200352 ↗
31. 10.1186/s13148‐015‐0151‐810.1186/s13148‐015‐0151‐8 ↗
32. 10.1016/j.bcp.2004.05.03710.1016/j.bcp.2004.05.037 ↗
33. 10.1007/s13238‐021‐00846‐710.1007/s13238‐021‐00846‐7 ↗
34. 10.1021/cr500452k10.1021/cr500452k ↗
35. 10.1038/s12276‐023‐01066‐110.1038/s12276‐023‐01066‐1 ↗
36. 10.1016/j.molcel.2021.03.00810.1016/j.molcel.2021.03.008 ↗
37. 10.1038/sj.onc.120923110.1038/sj.onc.1209231 ↗
38. 10.3390/cancers1312287210.3390/cancers13122872 ↗
39. 10.1186/s12967‐024‐04952‐y10.1186/s12967‐024‐04952‐y ↗
40. 10.1146/annurev‐biochem‐082520‐12541110.1146/annurev‐biochem‐082520‐125411 ↗
41. 10.1186/s13059‐020‐01991‐810.1186/s13059‐020‐01991‐8 ↗
42. 10.3389/fimmu.2022.86597510.3389/fimmu.2022.865975 ↗
43. 10.1158/0008‐5472.CAN‐20‐023310.1158/0008‐5472.CAN‐20‐0233 ↗
44. 10.3390/biom1303041710.3390/biom13030417 ↗
45. 10.1038/sj.onc.120923110.1038/sj.onc.1209231 ↗
46. 10.1021/jacs.7b1314110.1021/jacs.7b13141 ↗
47. 10.1016/j.tplants.2015.07.00510.1016/j.tplants.2015.07.005 ↗
48. 10.1242/jcs.26125010.1242/jcs.261250 ↗